Fig. 7.

Bestatin inhibits tumor growth in a PDX mouse model. (a) Mice bearing PDX tumors were treated or not treated with bestatin. The asterisks (*, **) indicate a significant (p < .05, p < .01, respectively) decrease in tumor volume in mice treated with bestatin compared with the control group. (b) Tumor weight was measured at the end of the study. The asterisk (*) indicates a significant (p < .05) decrease in tumor weight in bestatin-treated mice compared with control mice. The data are shown as mean values ± S.E., (n = 6). (c) LTB4 concentration was measured in mouse serum. The asterisks (*, **) indicate a significant (p < .05, p < .01, respectively) decrease in LTB4 concentration in bestatin-treated mice compared with control mice. (d) Photographs of tumors from each group are shown. (e) Bestatin treatment has no effect on the body weight of mice. (f) Immunohistochemistry analysis was used to determine the levels of BLT1, p-ERK1/2 (Thr202/Tyr204), c-Myc, and Ki-67 in bestatin-treated and control mice. Representative photographs for each protein and each group are shown. The integrated optical density (IOD) was evaluated using the Image-Pro Premier software (v.9.0) program (scale bar, 100 μm). The asterisks (*, **) indicate a significant (p < .05, p < .01, respectively) decrease in protein expression compared with the control group.